Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
University of Virginia
University of Pittsburgh
Cancer Research UK
Revolution Medicines, Inc.
UNICANCER
Pfizer
Nantes University Hospital
Innovent Biologics (Suzhou) Co. Ltd.
Revolution Medicines, Inc.
Fudan University
Jiangxi Provincial Cancer Hospital
Revolution Medicines, Inc.
Blokhin's Russian Cancer Research Center
MultiVir, Inc.
Sinocelltech Ltd.
Cambridge University Hospitals NHS Foundation Trust
Ministry of Scientific Research and Information Technology, Poland